Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR
A Open-label, One-arm Trial of Gefitinib Combined With Radiotherapy as Adjuvant Therapy in Completely Resected Patients With Pathological Stage IIIA-N2 Non-small Cell Lung Cancer Harbouring Sensitive Mutations of EGFR
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A NA clinical study on Lung Cancer, this trial is ongoing. The trial is conducted by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and has accumulated 7 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Feb 2026 — Present [monthly]
Unknown NA
Status: Not Yet Recruiting → Unknown
-
Sep 2024 — Feb 2026 [monthly]
Not Yet Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting NA
-
Nov 2022 — Jul 2024 [monthly]
Not Yet Recruiting NA
-
Jan 2021 — Nov 2022 [monthly]
Not Yet Recruiting NA
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Not Yet Recruiting NA
-
Jan 2018 — Jun 2018 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- China-Japan Friendship Hospital
- Chinese PLA General Hospital
- Peking University Cancer Hospital & Institute
- Qilu Pharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .